香港股市 將在 2 小時 開市

兆科眼科-B (6622.HK)

HKSE - HKSE 延遲價格。貨幣為 HKD。
加入追蹤清單
6.090-0.110 (-1.77%)
收市價: 04:08PM HKT

兆科眼科-B

No. 1 Meide 3rd Road
Pearl River Industrial Park Nansha District
Guangzhou
China
86 20 3906 2888
https://www.zkoph.com

版塊Healthcare
行業Biotechnology
全職員工179

高階主管

名稱標題支付行使價出生年份
Dr. Xiaoyi Li Ph.D.Chairman ,Exec. Director and CEO1963
Ms. Xinyan FengChief Financial Officer
Dr. Lit Fui LauChief Operating Officer
Mr. Xiangrong DaiExec. Director
Dr. Albert Tsai Jr.Chief Medical Officer
截止 為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 HKD。

描述

Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company, engages in the research, development, and commercialization of therapies that address unmet medical needs in the People's Republic of China. It is developing various drugs that cover ophthalmic indications affecting the anterior and posterior segments, including dry eye diseases, wet age-related macular degeneration, diabetic macular edema, myopia, and glaucoma. The company was formerly known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited was incorporated in 2017 and is headquartered in Guangzhou, the People's Republic of China.

公司管治

截至 無 止,兆科眼科-B 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中:無;董事會:無;股東權利:無;現金賠償:無。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。